SpectraCure AB (publ) (SPEC.ST)
SEK 1.77
(-0.45%)
SEK 1.77
(-0.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -9.22 Million SEK | -357.27% |
| 2022 | 3.58 Million SEK | 158.84% |
| 2021 | 1.38 Million SEK | -41.09% |
| 2020 | 2.35 Million SEK | -10.18% |
| 2019 | 2.61 Million SEK | -3.79% |
| 2018 | 2.72 Million SEK | 50.14% |
| 2017 | 1.81 Million SEK | 38.27% |
| 2016 | 1.31 Million SEK | 27.51% |
| 2015 | 1.02 Million SEK | -8.06% |
| 2014 | 1.11 Million SEK | -21.4% |
| 2013 | 1.42 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -653 Thousand SEK | -113.72% |
| 2024 Q1 | 4.76 Million SEK | 1596.86% |
| 2023 FY | -2.34 Million SEK | -165.38% |
| 2023 Q1 | 11.42 Million SEK | 586.84% |
| 2023 Q3 | 1.9 Million SEK | -2.61% |
| 2023 Q2 | 1.95 Million SEK | -82.88% |
| 2023 Q4 | -318 Thousand SEK | -116.68% |
| 2022 Q1 | 575 Thousand SEK | -20.03% |
| 2022 Q3 | 501 Thousand SEK | -40.71% |
| 2022 Q4 | 1.66 Million SEK | 232.14% |
| 2022 FY | 3.58 Million SEK | 158.84% |
| 2022 Q2 | 845 Thousand SEK | 46.96% |
| 2021 Q4 | 719 Thousand SEK | 15.41% |
| 2021 Q3 | 623 Thousand SEK | 400.97% |
| 2021 Q2 | -207 Thousand SEK | -182.8% |
| 2021 Q1 | 250 Thousand SEK | -87.18% |
| 2021 FY | 1.38 Million SEK | -41.09% |
| 2020 Q2 | 408 Thousand SEK | -12.63% |
| 2020 Q4 | 1.95 Million SEK | 164.95% |
| 2020 FY | 2.35 Million SEK | -10.18% |
| 2020 Q1 | 467 Thousand SEK | -66.57% |
| 2020 Q3 | 736 Thousand SEK | 80.39% |
| 2019 FY | 2.61 Million SEK | -3.79% |
| 2019 Q4 | 1.39 Million SEK | 108.51% |
| 2019 Q3 | 670 Thousand SEK | -12.87% |
| 2019 Q2 | 769 Thousand SEK | 41.36% |
| 2019 Q1 | 544 Thousand SEK | -64.42% |
| 2018 Q4 | 1.52 Million SEK | 104.41% |
| 2018 Q1 | 10 Thousand SEK | -98.0% |
| 2018 Q2 | 434 Thousand SEK | 4240.0% |
| 2018 Q3 | 748 Thousand SEK | 72.35% |
| 2018 FY | 2.72 Million SEK | 50.14% |
| 2017 Q1 | 429.2 Thousand SEK | -1.99% |
| 2017 FY | 1.81 Million SEK | 38.27% |
| 2017 Q2 | 428.3 Thousand SEK | -0.21% |
| 2017 Q3 | 455.41 Thousand SEK | 6.33% |
| 2017 Q4 | 499.35 Thousand SEK | 9.65% |
| 2016 Q3 | -72.58 Thousand SEK | -136.76% |
| 2016 Q1 | 721.43 Thousand SEK | 524.57% |
| 2016 Q4 | 437.89 Thousand SEK | 703.3% |
| 2016 FY | 1.31 Million SEK | 27.51% |
| 2016 Q2 | 197.46 Thousand SEK | -72.63% |
| 2015 Q1 | 403.08 Thousand SEK | 69.33% |
| 2015 Q4 | 115.51 Thousand SEK | -33.75% |
| 2015 Q3 | 174.36 Thousand SEK | -47.95% |
| 2015 Q2 | 334.96 Thousand SEK | -16.9% |
| 2015 FY | 1.02 Million SEK | -8.06% |
| 2014 FY | 1.11 Million SEK | -21.4% |
| 2014 Q1 | 293.27 Thousand SEK | 0.0% |
| 2014 Q2 | 191.56 Thousand SEK | -34.68% |
| 2014 Q3 | 395.18 Thousand SEK | 106.3% |
| 2014 Q4 | 238.04 Thousand SEK | -39.76% |
| 2013 FY | 1.42 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 274.117% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 103.068% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 103.068% |
| Arcoma AB | 11.07 Million SEK | 183.308% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 106.589% |
| BICO Group AB (publ) | 1.83 Billion SEK | 100.504% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 103.693% |
| CellaVision AB (publ) | 463.04 Million SEK | 101.992% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 407.741% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 67.541% |
| C-Rad AB (publ) | 66.01 Million SEK | 113.971% |
| Duearity AB (publ) | -4.17 Million SEK | -120.752% |
| Dignitana AB (publ) | 58.97 Million SEK | 115.64% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 77.935% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.069% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 81.634% |
| Iconovo AB (publ) | 17.57 Million SEK | 152.47% |
| Integrum AB (publ) | 690.56 Thousand SEK | 1435.579% |
| Luxbright AB (publ) | -2.79 Million SEK | -229.761% |
| Mentice AB (publ) | 236.38 Million SEK | 103.902% |
| OssDsign AB (publ) | 83.64 Million SEK | 111.026% |
| Paxman AB (publ) | 12.61 Million SEK | 173.094% |
| Promimic AB (publ) | 38.51 Million SEK | 123.947% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 81.828% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 157.511% |
| ScandiDos AB (publ) | 47.55 Million SEK | 119.394% |
| Sectra AB (publ) | 557.55 Million SEK | 101.654% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 108.463% |
| Senzime AB (publ) | 8.33 Million SEK | 210.601% |
| Stille AB | 132.17 Million SEK | 106.978% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 100.466% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 102.212% |